Aims: Studies of DNA methylomes hold enormous promise for biomedicine but are hampered by the technological challenges of analyzing many samples cost-effectively. Recently, a major extension of the previous Infinium HumanMethylation27 BeadChip ® (Illumina, Inc. CA, USA), called Infinium HumanMethylation450 (Infinium Methylation 450K; Illumina, Inc. CA, USA) was developed. This upgraded technology is a hybrid of two different chemical assays, the Infinium I and Infinium II assays, allowing (for 12 samples in parallel) assessment of the methylation status of more than 480,000 cytosines distributed over the whole genome. In this article, we evaluate Infinium Methylation 450K on cell lines and tissue samples, highlighting some of its advantages but also some of its limitations. In particular, we compare the methylation values of the Infinium I and Infinium II assays. Materials & methods: We used Infinium Methylation 450K to profile: first, the well-characterized HCT116 wild-type and double-knockout cell lines and then, 16 breast tissue samples (including eight normal and eight primary tumor samples). Absolute methylation values (b-values) were extracted with the GenomeStudio TM software and then subjected to detailed analysis. Results: While this technology appeared highly robust as previously shown, we noticed a divergence between the b-values retrieved from the type I and type II Infinium assays. Specifically, the b-values obtained from Infinium II probes were less accurate and reproducible than those obtained from Infinium I probes. This suggests that data from the type I and type II assays should be considered separately in any downstream bioinformatic analysis. To be able to deal with the Infinium I and Infinium II data together, we developed and tested a new correction technique, which we called 'peak-based correction'. The idea was to rescale the Infinium II data on the basis of the Infinium I data. While this technique should be viewed as an approximation method, it significantly improves the quality of Infinium II data. Conclusion: Infinium 450K is a powerful technique in terms of reagent costs, time of labor, sample throughput and coverage. It holds great promise for the better understanding of the epigenetic component in health and disease. Yet, due to the nature of its design comprising two different chemical assays, analysis of the whole set of data is not as easy as initially anticipated. Correction strategies, such as the peak-based approach proposed here, are a step towards adequate output data analysis. keywoRds: bisulfite-based method n dNA methylation n dNA methylome n epigenetics n epigenomics n Infinium I n Infinium II n Infinium Methylation 450k n peak-based correction
DNA methylation of cytosine residues is essential to the normal development and maintenance of gene-expression patterns [1] . In humans, it occurs mainly in the context of CpG dinucleotides, although the presence of 5-methylcytosine in a non-CpG context has been described in embryonic stem cells [2, 3] . Throughout the genome 70% of CpG sites are methylated [3] , but short regions of high CpG-density -called CpG islands (CGIs) -found in approximately 60% of gene promoters are usually unmethylated [4, 5] . In several diseases, DNA methylation landscapes display numerous alterations [6] . For instance in cancers, a global hypomethylation of the genome, paradoxically associated with silencing of tumor suppressor genes through promoter hypermethylation, is a widely reported event [6] [7] [8] .
Such alterations of DNA methylation in both cancer and other diseases have raised wide interest in developing large-scale DNA methylation profiling methods [7, 9] . Bisulfite genomic sequencing remains the gold standard, as it allows mapping at single-base pair resolution [10] [11] [12] . Combined with next-generation sequencing, it constitutes the best approach -in terms of accuracy, coverage and resolution -to decipher the complete DNA methylome [10] [11] [12] . Such an approach can allow for a comprehensive assessment of a small number of samples [3] . Biomarker research, however, requires effective high-throughput processing of hundreds or thousands of samples, for example, from clinical cohorts. The best compromise thus far in terms of reagent costs, time of labor, sample throughput and coverage may be the recently developed Infinium HumanMethylation450 BeadChip ® (Infinium Methylation 450K; Illumina, Inc. CA, USA). This new-generation array constitutes a major extension of the previous Infinium HumanMethylation27 BeadChip (Infinium Methylation 27K; Illumina, Inc. CA, USA) [13] . While it does not yield an integral map of the DNA methylome, Infinium Methylation 450K makes it possible to assess the methylation status of more than 480,000 cytosines distributed over the entire genome. Two recent reports have already shown the accuracy and reproducibility of this technology, notably by comparing the sample methylation profiles obtained using the Infinium 450K with ones produced by two other technologies previously developed by Illumina, Infinium 27K and GoldenGate [14] , and by whole-genome bisulfite sequencing [15] . Interestingly, while Bibikova et al. report a difference in performance between the two chemical assays used by this technology, Infinium I and Infinium II, they did not measure the consequences of this difference in performance, notably in the detection of differentially methylated cytosines [15] .
In the present study, we have further evaluated the Infinium Methylation 450K technology, focusing notably on these two different chemical assays used on this unique array. We proposed a way to overcome the difference in performance of these two assays.
Materials & methods
n Samples & DNA extraction HCT116 wild-type (WT) and HCT116 doubleknockout (DKO) cells were cultured in McCoy's 5A medium, supplemented with 10% fetal calf serum. Genomic DNA was extracted with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) including the recommended proteinase K and RNase A digestions. The eight archival fresh frozen breast tumor samples (BC) used in this study were from patients diagnosed at the Jules Bordet Institute between 1995 and 2003. In addition to the eight tumor samples, eight normal breast tissue samples (N) were selected as well. Genomic DNA from these frozen clinical samples was extracted from 10 µm sections with the Qiagen DNeasy Blood and Tissue Kit according to the supplier's instructions (Qiagen). The procedure included a proteinase K digestion at 55°C overnight. DNA was quantitated with the NanoDrop ® ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). For bisulfite pyrosequencing on breast tissue samples, four CpGs assessed on the Infinium 450K by the Infinium II assay were selected. Because we only had a limited quantity of material, a preamplification PCR (with EF and ER primers) was performed on bisulfiteconverted gDNA before the PCR amplification with biotinylated primers (F and RBio primers) for the pyrosequencing (with S primers). This strategy is described in details in [16] . Sequences of primers used for pyrosequencing on breast tissues are listed in SupplemenTary Table 3 . n Peak-based correction method When studied independently, the b-value distributions for both the type I and type II Infinium assays showed two modes corresponding to the unmethylated or methylated status of the interrogated cytosines. Plotting the b-value densities (kernel density estimation with a Gaussian smoothing function and a bandwidth = 0.05) for both assay types highlighted two clear peaks (an unmethylated peak and a methylated peak), whose positions seemed to be shifted between the type I and type II Infinium assays (Figure 1b, left part) . Using the peak summits, b-values could be corrected to match the same values for the methylated and unmethylated status of the interrogated cytosines and to cover the same range (Figure 1a & 1b) . The correction was performed as follows: The raw b-values were converted to M-values (see [17] for details) using the relation: M-value = log 2 (b-value/(1 -b-value). The methylated peaks and unmethylated peak summits were determined for both Infinium I and II using a kernel density estimation with a Gaussian smoothing function and a bandwidth = 0.5. Unmethylated peak summits were computed as S U = argmax (density M-value) for All calculations were performed with the freely available R software [102] . n Bioinformatic analyses Using Infinium annotation data, Infinium sites (cytosines) were classified according to their relation to CGIs and to the closest annotated gene. Regarding their relation to CGIs, the sites were classified in three categories: sites located inside a CGI, sites located in the vicinity of a CGI (<2000 bp: CGI shores), and sites unrelated to any CGI (>2000 bp: distant). As regards their relation to annotated genes, Infinium sites were categorized as inside the promoter (promoter) if they were inside the 1500-bp region upstream from the transcriptional start site, inside the 5´-UTR region, inside the gene body if their location matched the corresponding gene annotation, and inside the 3´-UTR region. Sites related to multiply annotated transcripts falling into several location categories depending on the considered transcript were classified as multiple locations. Finally, sites unrelated to any annotated gene were classified as intergenic.
Concerning differentially methylated sites, for the HCT116 samples, they were selected on the basis of the absolute methylation change between the means of the three replicates of WT and DKO samples (r1, r2 and r3): a site was considered as differentially methylated if the mean b-value for WT samples was >0.8 and the mean b-value for DKO samples was <0.2. For breast tissue samples, sites were considered differentially methylated when the relative difference in methylation between the means of normal and cancer samples was greater than 0.2 (abs[mean{BC} -mean{N}] >0.2). Furthermore, we retained only the sites showing a statistically significant difference according to the Mann-Whitney test, with a false discovery rate set at 0.05 (computed using the Benjamini Hochberg procedure).
All calculations were performed with the freely available R software [102] .
Results n Design of the Infinium Methylation 450K array
The general principle of the Inf inium Methylation techniques (both Infinium 27K and Infinium 450K) is to evaluate cytosine methylation through quantitative 'genotyping' of the C/T polymorphism generated by the bisulfite conversion, with a throughput of 12 samples per slide [13] . Whereas Infinium 27K uses only one type of assay (Infinium I) [13] , Infinium 450K is a hybrid of two different assays (Infinium I and II) (Figure 2 ) allowing coverage of many more cytosines than the previous version, Infinium 27K. Infinium I exploits two different probes (corresponding to the methylated and unmethylated alleles) located on two different bead types, and the methylated and unmethylated signals are generated in the same color channel (Figure 2a) . Infinium II uses only one bead type with a unique type of probe allowing detection of both alleles. The methylated and unmethylated signals are generated respectively in the green and the red channels (Figure 2b) . In both cases, the percentage of methylation of a given cytosine is reported as a b-value corresponding to the ratio of the methylated signal over the sum of the methylated and unmethylated signals.
Infinium 450K covers 96% of the CGIs. Multiple CGI shores and CpG sites located far from islands are also highly represented (Figure 3a) . In addition, 99% of the RefSeq genes are covered overall, and the cytosine sites interrogated are located across gene regions including not only promoter regions but also 5´-UTRs, gene bodies, and 3´-UTRs (Figure 3b) . Intergenic regions are included as well. This seemed particularly important in the light of recent data suggesting that one should look beyond CGI promoter methylation [18] . It is noteworthy that, except for those located within CGIs, the methylation status of cytosines is more frequently assessed by the Infinium II than by the Infinium I assay Figure 3) . It is therefore important to evaluate how efficiently the Infinium II assay, newly introduced on Infinium methylation arrays, detects precise methylation levels. n Divergence of results obtained with the Infinium I & Infinium II assays To evaluate Infinium Methylation 450K, we first profiled the well-characterized HCT116 human colon cancer cell line and a derivative thereof (DKO) where DNA methylation is strongly reduced because of deletion of both the DNMT1 and DNMT3B DNA methyltransferases [19] . As previously shown [14] , this technology proved highly reproducible (average Pearson correlation between three replicates (r1, r2 and r3): mean R 2 = 0.992 and 0.988 for HCT116 WT and DKO, respectively) (SupplemenTary Figure 2) .
We next considered the data from Infinium I and Infinium II separately in order to compare these assays in terms of performance. Looking at the range of b-values, we remarked that the b-values obtained from the Infinium II probes displayed a range smaller than those obtained from the Infinium I probes (0.971 and 0.922 for Infinium I and II, respectively) (Figure 1a , left part). On b-value density plots, both assays displayed a bimodal distribution with two peaks corresponding to unmethylated and fully methylated CpGs, but we noticed a shift of the peaks for Infinium II with respect to those obtained with Infinium I (Figure 1b, left  part) . These differences cannot be explained 
genomic contexts of the cytosines interrogated by the Infinium I and II assays (SupplemenTary Figure 3) . Our data suggest that the Infinium II assay is less sensitive for the detection of extreme methylation values (i.e., 0 and 1) than the Infinium I assay. This is probably due to the dual-channel readout used in the former (Figure 2b ). In addition, looking at the average probe-wise variance, we observed a greater variance between replicates for the Infinium II probes than for the Infinium I probes (standard deviation = 0.029 for Infinium II vs 0.008 for Infinium I) ( Figure 1C, left part) www.futuremedicine.com single sample, two different types of data are actually generated. To get around this limitation, we looked for a way to deal simultaneously with data coming from the two Infinium assays by correcting the b-values generated from the Infinium II assay. Unfortunately, the methods used classically in gene-expression profiling for interarray normalization (e.g., quantile normalization) cannot be used to correct the above-mentioned data for several reasons:
The Infinium I and Infinium II assays concern only one sample, not two different ones; The two assays do not interrogate the same number of CpGs ( Figure 3) ; The two assays do not interrogate the same CpGs, resulting in a disproportion of the number of methylated and unmethylated sites evaluated between the two assays (Figure 1b) .
We thus sought another way to correct the data. To this end, we developed and tested a new correction technique, which we called 'peakbased correction'. This method consists in rescaling the Infinium II data to make the unmethylated and methylated peaks of the two assays match (see SupplemenTary Figure 1 and 'Materials & methods'). As shown in the right part of Figure 1a for the HCT116 WT sample, this yielded for the Infinium II assay a range of b-values similar to that of the Infinium I assay. As expected, after peak-based correction, the unmethylated and methylated peaks of the two assays matched (Figure 1b, right part) . In the particular case of DKO cells, displaying no methylated peak, only the unmethylated values were subjected to the correction (see Materials & methods) . This resulted in matching of the unmethylated peaks of the two assays without alteration of the methylated values (SupplemenTary Figure 4) . One should note that, as only the unmethylated values were stretched, there appeared to be a little break between the methylated and unmethylated values (SupplemenTary Figure 4) .
Remarkably, peak-based correction strongly decreased the average probe-wise variance for Infinium II (standard deviation = 0.011), reducing it to the level of variance of Infinium I ( Figure 1C,  right part) . Rescaling of the Infinium II b-values to match the Infinium I range tends to move the b-values corresponding to the unmethylated state closer to zero and those corresponding to the methylated state closer to one, reducing the differences between unmethylated or methylated values and thus reducing the variance between replicates. Moreover, although already strong, the correlation between the Infinium II and bisulfite pyrosequencing data was further enhanced by this correction (Pearson's correlation: R 2 = 0.951 and 0.967, without and with peak-based correction respectively) (Figure 4a) . Figure 4b and Table 1 clearly show that applying peak-based correction to the Infinium II data allowed to decrease the differences between methylation values obtained from Infinium and bisulfite pyrosequencing data (see also SupplemenTary Table 2 ). This suggests that values having undergone the correction are more precise than values which have not. It is of note that, as shown in Figure 4C , the benefit of using peak-based correction was specific to extreme methylation values (i.e., close to 0 or 1), being lower for intermediate methylation values (close to 0.5). Thus, while this approach should be viewed as an approximation method, peak-based correction considerably reduces the difference between b-values provided by the Infinium I and Infinium II assays, by correcting the Infinium II b-values. It might not be the perfect method but it makes it possible to consider the two types of data as a single set, thus facilitating downstream bioinformatic analyses. n Applicability of Infinium 450K & peak-based correction to clinical tissue samples Having addressed this technical issue linked to the array design, we next examined the applicability of Infinium Methylation 450K to clinical sample profiling. We profiled eight normal breast samples and eight primary breast cancer samples. On density plots, the b-values still showed a bimodal distribution and, as for the cell lines, we observed a shift of the methylated and unmethylated peaks of the Infinium II b-values, with respect to those of the Infinium I b-values (Figure 5a, left part) . It is noteworthy that, for the tissue samples, both peaks were less pronounced than for the cell lines (see also SupplemenTary Figure 5 ). In particular, the methylated peaks were broader than those observed for HCT116 cells (compare Figure 5a with Figure 1b) . This likely reflects the mixture of different cell types present in these clinical samples (data not shown). It might render difficult the precise detection of peak summits and therefore might be a problem for applying the peak-based correction. Nevertheless, when we applied the correction to our tissue data, we managed, as for the HCT116 samples, to make the methylated and unmethylated peaks of the two assays coincide (Figure 5a, right part) . Moreover, upon performing bisulfite pyrosequencing on a few tissue samples, we showed that globally, the Infinium methylation values subjected to peakbased correction were closer to those obtained by bisulfite pyrosequencing than were uncorrected values. (Figure 5b) . Thus, Infinium 450K is applicable to tissue samples as well, and the peak-based correction allows to improve the data quality.
n Improving of the detection of differentially methylated cytosines by correcting the Infinium II data The fact that peak-based correction increases the b-value range and decreases the probe-wise variance for the Infinium II assay suggests that (Table 2) . Furthermore, bisulfite pyrosequencing data applied to two cytosines detected as differentially methylated on the basis of the corrected Infinium data (but not on the basis of the uncorrected Infinium data) confirmed that the two cytosines were really differentially methylated and that they were missed if the correction was not applied (Figure 6 ). We then performed the same experiment on breast tissue samples by comparing normal tissues and tumors. In this case, a cytosine was considered differentially methylated if the corresponding relative difference in methylation between the mean of the N and BC samples was at least 0.2 and statistically significant (as assessed by the Mann-Whitney test, false discovery rate = 0.05), (see Materials & methods). As previously shown for HCT116 cell lines, applying the peak-based correction made it possible to detect more differentially methylated cytosines (SupplemenTary Table 4 ). This clearly suggests that applying a correction to the Infinium II data, such as the peak-based correction described here, can help to identify differentially methylated cytosines.
discussion
The present report is an evaluation of the recently released Infinium Methylation 450K technology, assessing the quality of the output data generated by the two chemical assays present on this array. The previous version of the array, Infinium 27K, uses only the Infinium I chemical assay. On the new Infinium 450K array, approximately a third of the cytosines are interrogated with Infinium I, but roughly twothirds are interrogated with another chemical assay, called Infinium II. Here, after examining the data globally and showing their accuracy and reproducibility, we have also directly compared the b-values retrieved from the two Infinium assays and highlighted some significant differences between the two sets of data. Recently, two other groups also studied this new technology and demonstrated its accuracy and reproducibility [14, 15] . Our data are in agreement with those two studies. In one of them, the authors noticed a difference between the ranges of b-values retrieved from the two Infinium assays [15] . In our study, we have also noticed this difference in terms of b-values distribution, and in addition, we have highlighted a difference in the average probe-wise variances between replicates. The Infinium II assay is thus less accurate and reproducible, and notably less sensitive for the detection of extreme methylation values (e.g., 0 and 1), than the Infinium I assay. This is really noteworthy, as it means that Infinium I and Infinium II data are not directly comparable.
We thus reveal here an additional bias linked to the use of this technology. Actually, although this was not the focus of the present study, it is important to bear in mind that other potential biases can be observed with this technology:
As with all bisulfite-based methods, incomplete bisulfite conversion can introduce a bias; As with all array-based methods, Infinium Methylation 450K results are probably subject to technical confounding, including a batch effect [20] (although this has yet to be demonstrated); SNPs sometimes contained in probes can interfere with methylation level detection [21] .
The differences revealed here between Infinium I and II data render downstream bioinformatic analysis more complex. To make the two sets comparable, we have developed a method for correcting the Infinium II b-values. We called it peak-based correction. It consists in rescaling the Infinium II data. Although approximate, this correction method considerably improves the accuracy and reproducibility of Infinium II data, notably for extreme methylation values (close to 0 or 1) and reduces the bias. Furthermore, it facilitates the detection of differentially methylated cytosines that can be missed if the Infinium II data are not corrected.
After demonstrating the robustness of the technique and providing a mean of correcting the bias linked to the use of two different assays on the same array, we have demonstrated the applicability of this technology to profiling www.futuremedicine.com clinical tissue samples. This is really important as it makes this technology one of the most attractive for large clinical studies. It is worth noting, however, that this technology has a major limitation, that is its inability to differentiate methylation from hydroxymethylation, another chemical modification that can be found on cytosine residues [22] . In the future, a challenge will thus be to develop new genome-wide technologies capable of distinguishing these two types of modified cytosines. 
Conclusion
In conclusion, our study reveals the Infinium Methylation 450K technology as a highly accurate and reproducible technology for genomescale DNA methylation profiling, even though it presents a bias linked to its particular design. This bias should be corrected with a method -such as the peak-based correction method presented here -before further downstream analysis. Compared with truly genome-wide bisulfite sequencing, the focus of Infinium 450K on
